Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $281,500.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock traded up $0.49 during trading hours on Tuesday, reaching $56.77. The company had a trading volume of 716,947 shares, compared to its average volume of 1,357,498. The firm has a market cap of $7.22 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business has a fifty day simple moving average of $51.00 and a 200 day simple moving average of $54.35.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HALO. AQR Capital Management LLC raised its stake in Halozyme Therapeutics by 5.0% in the second quarter. AQR Capital Management LLC now owns 47,773 shares of the biopharmaceutical company’s stock valued at $2,501,000 after purchasing an additional 2,265 shares in the last quarter. Creative Planning raised its position in shares of Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after buying an additional 11,249 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $1,075,000. SG Americas Securities LLC grew its position in Halozyme Therapeutics by 365.6% in the third quarter. SG Americas Securities LLC now owns 12,186 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 9,569 shares in the last quarter. Finally, Park Avenue Securities LLC increased its stake in Halozyme Therapeutics by 25.2% in the third quarter. Park Avenue Securities LLC now owns 11,638 shares of the biopharmaceutical company’s stock valued at $666,000 after acquiring an additional 2,343 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on HALO shares. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.